Phase 3 Non-Alcoholic Fatty Liver Disease Trial, Recruiting (NCT03925701)

Phase 3 Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT03925701 Sponsor: Sherief Abd-Elsalam Condition: Non-Alcoholic Fatty Liver Disease

Printed from Voxsanity (voxsanity.com.au) — NCT03925701 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Non Alcoholic Fatty Liver Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with a liver condition called fatty liver disease (NAFLD — where fat builds up in the liver not caused by alcohol)
You have also been diagnosed with type 2 diabetes

Who may not be able to join:

You have a liver infection caused by a virus (such as hepatitis B or hepatitis C)
Your liver disease is considered more severe, based on a scoring system doctors use to measure liver function (called the Child score — confirm with trial site)
You have problems with your kidneys (reduced kidney function)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 14 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Aya G Moussa, Msc, Tanta University - Faculty of Pharmacy

Phone: 00201147773440

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT03925701

Sponsor: Sherief Abd-Elsalam

Phase: Phase 3

Status: Recruiting

Condition: Non-Alcoholic Fatty Liver Disease

Trial contact: 00201147773440

More information: https://clinicaltrials.gov/study/NCT03925701

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with a liver condition called fatty liver disease (NAFLD — where fat builds up in the liver not caused by alcohol)
You have also been diagnosed with type 2 diabetes

Who may not be able to join:

You have a liver infection caused by a virus (such as hepatitis B or hepatitis C)
Your liver disease is considered more severe, based on a scoring system doctors use to measure liver function (called the Child score — confirm with trial site)
You have problems with your kidneys (reduced kidney function)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 14 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Sherief Abd-Elsalam

Registry

ClinicalTrials.gov

Start date

1 April 2019

Est. completion

1 December 2028

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

number of patients with improved nafld and insulin resistance

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov